Macrophages are a major source of lipid mediators in the human lung. Expression and contribution of cytosolic (cPLA 2 ) and secreted phospholipases A 2 (sPLA 2 ) to the generation of lipid mediators in human macrophages are unclear. We investigated the expression and role of different PLA 2 s in the production of lipid mediators in primary human lung macrophages. Macrophages express the alpha, but not the zeta isoform of group IV and group VIA cPLA 2 (iPLA 2 ). Two structurally-divergent inhibitors of group IV cPLA 2 completely block arachidonic acid release by macrophages in response to non-physiological (Ca 2+ ionophores and phorbol esters) and physiological agonists (lipopolysaccharide and Mycobacterium protein derivative). These inhibitors also reduce by 70% the synthesis of platelet-activating factor by activated macrophages. Among the full set of human sPLA 2 s, macrophages express group IIA, IID, IIE, IIF, V, X and XIIA, but not group IB and III enzymes. Me-Indoxam, a potent and cell impermeable inhibitor of several sPLA 2 s, has no effect on arachidonate release or platelet-activating factor production. Agonist-induced exocytosis is not influenced by cPLA 2 inhibitors at concentrations that block arachidonic acid release. Our results indicate that human macrophages express cPLA 2 -alpha, iPLA 2 and several sPLA 2 s. Cytosolic PLA 2 -alpha is the major enzyme responsible for lipid mediator production in human macrophages.
Introduction
Macrophages are the predominant immunocompetent cells in the lung where they play a pivotal role in immune and inflammatory reactions associated with diseases such as chronic obstructive pulmonary disease [1] , bronchial asthma [2] , interstitial lung disease [3] , infections [4] , and cancer [5] . These cells are one of the major sources of arachidonate-derived eicosanoids in the human lung, producing primarily 5-HETE and LTB 4 and, to a lesser extent, cysteinyl leukotrienes (LTC 4 , LTD 4 and LTE 4 ) and prostanoids (PGE 2 , PGF 2 α and TXA 2 ) [6] [7] [8] . In addition, human lung macrophages produce the pleiotropic lipid mediator platelet activating factor (PAF) [9] .
The synthesis of eicosanoids and PAF in mammalian cells is biochemically linked [10] . The hydrolysis of 1-alkyl-2-arachidonoylsn-glycero-3-phosphocholine, catalyzed by one or more phospholipases A 2 1 (PLA 2 s), is the initial biosynthetic step to generate free arachidonic acid (AA) and 1-alkyl-2-lyso-sn-glycero-3-phosphocholine, which are the precursors of eicosanoids and PAF, respectively. Different PLA 2 s have been identified and characterized in mammalian cells [11] . Known enzymes include high molecular weight, calciumdependent and calcium-independent, cytosolic PLA 2 s (cPLA 2 s), and low molecular weight, calcium-dependent, secreted PLA 2 s (sPLA 2 s).
The α-isoform of cPLA 2 (cPLA 2 -α, also known as group IVA PLA 2 , GIVA) is thought to play a critical role in agonist-stimulated AA release leading to eicosanoid production in the majority of mammalian cells [12] . Upon cell activation cPLA 2 -α is activated by a rise in intracellular calcium, by phosphorylation [13] , and possibly by specific phospholipids including phosphatidylinositol-4,5-bisphosphate [14] and ceramide-1-phosphate [15] .
Studies on the involvement of cPLA 2 s in human cells usually rely on pharmacological inhibition of these enzymes. Early studies with the potent cPLA 2 -α inhibitor AACOCF 3 provided evidence that this enzyme was responsible for most of the AA released in thrombinand collagen-stimulated human platelets [16, 17] . Two new classes of cPLA 2 -α inhibitors have been recently reported. The pyrrolidinecontaining compounds, including pyrrophenone [18] and pyrrolidine-1 [19] , have been shown to be highly potent inhibitors of cPLA 2 -α without influence on the β-and γ-isoforms of cPLA 2 [13, 20] , on the calcium-independent cytosolic PLA 2 (GVIB), and on several sPLA 2 s [20] . The other class includes 1,3-diphenoxyacetone inhibitors of cPLA 2 -α that are much more potent than AACOCF 3 (compound 22 of [21] , referred to as AZ-1 in the present study).
Recent studies with human peripheral blood neutrophils have shown that the cPLA 2 -α inhibitor pyrrolidine-1 completely blocks AA release and LTB 4 production as well as PAF production in response to a variety of physiologically-relevant agonists [22, 23] . Inhibition of lipid mediators by pyrrolidine-1 was virtually identical to that observed in bone marrow derived neutrophils from cPLA2-α-deficient mice [23] . Together, these observations indicate that cPLA 2 -α is the key enzyme for the generation of lipid mediators in several inflammatory cells. However, there is also evidence that other PLA 2 s may contribute to AA mobilization when cPLA 2 -α is blocked [24] . For example, a new GIVF cPLA 2 isoform, termed cPLA 2 -ζ, was recently discovered. This isoform displays similar kinetic properties to cPLA 2 -α, and show similar sensitivity to the cPLA 2 -α inhibitors pyrrolidine-1, pyrrophenone, Wyeth-1 [24] and AZ-1 (Leslie, C. and Gelb, M.H., unpublished data). These inhibitors block AA release in serum-stimulated lung fibroblasts that are prepared from cPLA 2 -α deficient mice, an effect that is likely due to inhibition of cPLA 2 -ζ [24] .
Ten different sPLA 2 s have been discovered in humans and mice [11] . In contrast to cPLA 2 s, sPLA 2 s are usually stored within cytoplasmic granules or pass through the classical secretory pathway to be released in the extracellular environment upon appropriate stimulation of the cell. The possible role of one or more sPLA 2 s in generating AA for eicosanoid production in mammalian cells is under active investigation. Recent studies with zymosan-stimulated mouse peritoneal macrophages show that disruption of the GV gene leads to an approximate 50% reduction in AA release [25] . In addition, studies with GV-and GX-deficient mice show that these enzymes play a significant role in promoting airway inflammation and eicosanoid production in a mouse model of asthma [26, 27] . This plus the observation that cPLA 2 -α gene disruption nearly completely eliminates AA release in the same cell/agonist system suggests that some sPLA 2 s, while not effective per se, can potentiate the action of cPLA 2 -α. Other studies confirmed this sPLA 2 -cPLA 2 -α interaction [28] [29] [30] [31] , but the molecular basis and directionality of this crosstalk is not understood. Thus, while the central role of cPLA 2 -α in eicosanoid generation is well established, other cPLA 2 s and sPLA 2 s may contribute, under certain circumstances, to provide AA or lyso-PAF available for lipid mediator biosynthesis.
While cPLA 2 -α appears to be expressed in virtually all mammalian cells, the expression of other members of the PLA 2 family is rather heterogeneous [32] . Defining the full set of the PLA 2 s expressed in inflammatory cells is crucial to understand the role of these enzymes in eicosanoid and PAF metabolism. Data on PLA 2 expression in macrophages derive mostly from studies in murine or guinea pig cells. However, macrophages from rodents exhibit marked biochemical and functional differences from human macrophages. For example, activated human lung macrophages synthesize predominantly 5-lipoxygenase metabolites [6, 7] , whereas murine macrophages produce both cyclooxygenase and lipoxygenase metabolites [33, 34] . In addition, macrophages isolated from distinct anatomical sites, e.g., pulmonary versus peritoneal, show a different ability to synthesize eicosanoids and PAF [35] . In most cases, studies on AA metabolism in human lung macrophages have been done by using alveolar macrophages obtained from bronchoalveolar lavage fluid [6, 36] . However, the human lung contains different subpopulations of macrophages distinct by morphological, biochemical and functional characteristics [37] [38] [39] . In this study we examined the expression of the complete set of cPLA 2 s and sPLA 2 s at both the mRNA and protein level in primary macrophages purified from the whole lung tissue. Therefore, the population of macrophages used in this study is representative of all the subsets of macrophages present in the human lung.
Materials and methods

Reagents
The following were purchased from Sigma: Fatty acid-free HSA and BSA, Percoll ® , piperazine-N,N′-bis-2-ethanesulfonic acid (PIPES), Triton X-100, L-glutamine, antibiotic-antimycotic solution (10,000 UI/ ml penicillin, 10 mg/ml streptomycin, and 25 μg/ml amphotericin), phenolphthalein glucuronide, lipopolysaccharide (LPS; from E. coli serotype 026:B6), and phorbol myristate acetate (PMA Mycobacterium tuberculosis purified protein derivative (PPD) and lipoarabinomannan (LAM) were a generous gift from Chiron S.r.l. A lyophilized stock of 25 mg of PPD and LAM were resuspended in 5 ml of PBS (150 mM NaCl, 3 mM KCl, 10 mM Na 2 HPO 4 , 1 mM KH 2 PO 4 , pH 7.4) and dialyzed (12,000-14,000 MW cut-off) against PBS overnight at 4°C. The cPLA 2 -α inhibitors pyrrolidine-1 and AZ-1 were synthesized as described [21, 22] . The sPLA 2 inhibitor Me-Indoxam was prepared as described [40] . The cell line HT-29 was purchased from ATCC. Recombinant cPLA 2 -α was produced as described [41] .
Isolation and purification of human lung macrophages
Macrophages were obtained according to human subject research guidelines of the institutions University of Naples Federico II and University of Washington. Macrophages were isolated from the lung parenchyma of patients undergoing thoracic surgery by flotation over Percoll ® density gradients, as previously reported [42] . The cells were suspended (10 6 cells/ml) in RPMI containing 5% FCS, 2 mM Lglutamine, and 1% antibiotic-antimycotic solution and incubated in 24-well plates. After 12 h, the medium was removed and the plates were washed with RPMI. More than 98% of adherent cells were macrophages as assessed by α-naphthylacetate esterase staining [42] .
RNA isolation and qPCR
Adherent macrophages were incubated (37°C, 24 h) in RPMI containing 1% glutamine and 1% antibiotic/antimycotic solution with or without LPS (3 μg/ml). Total RNA extraction from macrophages obtained from 5 donors was performed using the SV total RNA isolation system (Promega). In the final step, the RNA was treated with RNasefree DNase I and was suspended in DEPC treated water. RNA concentrations were determined by OD 260 using a Nanodrop apparatus, and RNA quality was evaluated by analysis on an Agilent Bioanalyzer.
First-strand cDNA was synthesized from 5 μg of total RNA using 100 U of MMLV reverse transcriptase (Promega) in a final volume of 50 μl with 500 ng of random primers (Promega). Quantitative PCR (qPCR) was carried out in 96-well ABgene plates using the GENEAMP 5700 sequence Detection System apparatus (Applied Biosystems) with the qPCR Master Mix Plus for SYBR R Green I (Eurogentec). All reactions were performed in a total volume of 16 μl and contained 50 ng of reverse transcribed RNA (based on the initial RNA concentration) and 250 nM of each primer set. The primer sets were designed using the Primer Express program from Applied Biosystems for the following human genes PLA2G2A (NM_000300), PLA2G2D (NM_012400), PLA2G2E (NM_0145891), PLA2G2F (NM_022819), PLA2G3 (NM_015715), PLA2G5 (NM_000929), PLA2G10 (NM_003561), PLA2G12A (BC_017218), PLA2G12B (NM_032562), cPLA 2 ζ (NM_213600), and iPLA 2 β (NM_003560). The primer sets were designed to span an intron in order to avoid amplification from potential traces of genomic DNA in the total RNA preparations. No amplification signal was obtained using human genomic DNA as template in the qPCR (not shown hGAPDH-R, GCAACAATATCCACTTTACCAGAGTTAA; 2) hGIIA-F, GGCACCAAATTTCTGAGCTACA; hGIIA-R, TTATCACACTCACACAGTTGACTTCTG;
3) hGIID-F, GCAGAGGCCAACCCAAAGA; hGIID-R, CAGGTGGTCATAGCAGCAGTCA; 4) hGIIE-F, TGGGCTGTGAGCCCAAA; hGIIE-R, GCCGGCGCAGAAAATG; 5) hGIIF-F, GGCCAGCCCAAGGATGA; hGIIF-R, TGGTCAAAGAGTTCCTGGTAGCA; 6) hGIII-F, GGCACAACCTGCTTCAAGCT; hGIII-R, CGGGCTGACACCCTGATG; 7) hGV-F, AAGGATGGCACCGATTGGT; hGV-R, CGAATGTTGCAGCCCTTCTC; 8) hGX-F, TGGCAGTGCGTCAATCAGA; hGX-R, TTGCACAACAGTTCTTGGCATT; 9) hGXIIA-F, TCCACTGTTTGGTGTTCATCTTAAC; hGXIIA-R, TCATAGCACCTGTCGTGTTGGT; 10) hGXIIB-F, GCGGAGTCTGGGCTTTGTC; hGXIIB-R, CACGGTGTTGAACACAGTGTCA; 11) hcPLA2zeta-F, AAGAGCTGCAGGTGGAATTTG; hcPLA2zeta-R, CAGAACCCCGTTGGTGATG; 12) hTOP1-F, CCCTGTACTTCATCGACAAGC; hTOP1-R, CCACAGTGTCCGCTGTTTC.
cPLA 2 -α immunoblotting analysis
Washed macrophages (3 × 10 5 ) were lysed in ice cold lysis buffer (50 mM Hepes, pH 7.4, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 10% glycerol, 1% Triton X-100 with freshly added protease inhibitors: 10 μg/ ml aprotinin, 10 μg/ml leupeptin and 1 mM PMSF) on ice for 30 min. After centrifugation for 20 min at 12,000 ×g at 4°C, the protein concentration in the supernatant was measured using a Bradfordbased assay (BioRad). Each lane of an 8% polyacrylamide gel was loaded with 60 μg of cell extract protein. After blotting, cPLA 2 -α was detected with a polyclonal antiserum [44] at a dilution of 1/1000. This was followed by detection with ECL (GE Biosciences).
2.5. Time-resolved fluorescence immunoassay (TRFIA) of sPLA 2 s
Two milliliters of antiserum was mixed with 8 ml of binding buffer (20 mM sodium phosphate, pH 7.0, filtered 0.45 μm), and the sample was loaded onto a 1 ml HiTrap protein A HP column (GE Biosciences) at a flow rate of 1 ml/min at room temperature. The column was washed with the same buffer until the OD 280 reached a minimum. The IgG fraction was eluted with 10 ml of elution buffer (100 mM glycine, pH 2.7, filtered) with collection of the OD 280 peak (about 3 ml) into a tube pre-loaded with 0.3 ml of 1 M Tris, pH 8.0. Purified IgG was stored at −20°C. Before use it was dialyzed against 4 portions of 10 mM sodium phosphate, pH 7.0 at 4°C for 1, 2, 5 and 12 h (50 volumes each). The protein concentration was measured with the Bradford assay (BioRad). A portion of sample containing 2 mg of IgG was lyophilized and stored dessicated at −20°C. The remainder was stored in 0.5 ml aliquots at −20°C. The lyophilized IgG was dissolved in 0.27 ml of purified water (Milli-Q, Millipore) and 30 μl of 1 M Na 2 CO 3 was added. The pH was checked by spotting a small aliquot onto moistened pH paper (adjusted to 9-9.5 when necessary). A 0.1 ml aliquot of labeling reagent (1 mg of DELFIA Eu-N1 ITC, Perkin Elmer) dissolved in 0.5 ml of purified water, stored −20°C) was added, and the sample was mixed gently and allowed to sit at 4°C. The sample was centrifuged at ∼12,000 ×g for 3 min prior to loading onto a 2 × 60 cm Superdex 200 column (GE Biosciences) pre-equilibrated in TSA buffer (50 mM Tris, pH 7.8, 0.9% NaCl, 0.05% NaN 3 ) at 1 ml/min at room temperature. Prior to use the column was decontaminated by running 10 mM phthalate, pH 4.1, 0.01% diethylenetriaminepentaacetic acid and then preconditioned by running 7.5 mg BSA in TSA buffer. One milliliter fractions were collected, which were analyzed for europium fluorescence (see below). The protein concentration was measured by a Bradford-based assay, and if less than 0.1 mg/ml, stabilizer (Perkin Elmer, 7.5% heavy metal free BSA) was added to give a final albumin concentration of 0.1%.
One hundred microliters of coating solution (10 μg/ml purified, unconjugated IgG, diluted into filtered 0.1 M sodium phosphate, pH 4.9 just prior to use) was added per well of a NUNC 8 × 12 DELFIA strip plate (Perkin Elmer). The strips were incubated in a sealed container with TSA buffer moistened paper towels for 24 h at room temperature. The solution was removed by aspiration, and 300 μl per well of blocking buffer (50 mM Tris, pH 7.8, 0.9% NaCl, 6% D-sorbitol, 1% BSA, 1 mM CaCl 2 , filtered) was added, and the strips were incubated overnight at room temperature in the buffer saturated container.
Samples were diluted in assay buffer (50 mM Tris, pH 7.8, 0.9% NaCl, 0.05% NaN 3 , 0.5% BSA, 0.01% Tween 40, 20 μM diethylenetriaminepentaacetic acid) to give a total volume of 100 μl. Blocking buffer was removed by aspiration from strip wells, and wells were washed twice with 0.3 ml portions of washing solution (50 mM Tris, pH 7.8, 0.9% NaCl, 0.05% NaN 3 , 0.02% Tween-20). Diluted sample was added to each IgG-coated well followed by incubation for 30 min at room temperature with agitation on an orbital shaker. Liquid was aspirated away, and the well was washed with four 0.3 ml portions of washing solution. Europium conjugated IgG was diluted in assay buffer, diluted solution was added to each well followed by incubation for 30 min at room temperature with agitation on the shaker. Liquid was aspirated away, and the well was washed with another four 0.3 ml portions of washing solution. Enhancement solution (100 μl Perkin Elmer) was added to each well, and incubation on the shaker was continued for 15 min. Time resolved, europium fluorescence was measured with a Victor 1420 Multilabel Counter using the protocol from the manufacturer. To check linearity and sensitivity, standard curves were made using known amounts of recombinant sPLA 2 (produced as described [40] ) after dilution in assay buffer. Approximate detection limits (pg sPLA 2 per assay well) were: GIB, 10; GIIA, 20; GIID, 500; GIIE, 40; GIIF, 300; GIII, 300; GV, 60; GX, 4; GXIIA, 600. 
AA release
, where R is the release in samples treated with the inhibitor, R b is the release in unstimulated samples and R max is the release in samples stimulated in the absence of the inhibitor.
PAF biosynthesis
Freshly isolated macrophages (10 7 cells/tube) were suspended in 1 ml of PCG buffer containing 0.5 mg/ml HSA, preincubated (30 min, 37°C) with increasing concentrations (0.01 to 10 μM) of pyrrolidine-1 or AZ-1 and then stimulated (10 min, 37°C) with 1 μM A23187 in the presence of 2 nmol of [ 3 H]acetic acid (≈7 μCi/tube) [9] . Reactions were stopped by the addition of 2 ml of methanol and 1 ml of chloroform. Unlabeled PAF (50 μg/tube) was added as a carrier immediately before lipid extraction. Lipids were extracted with the technique of Bligh and Dyer and separated by thin layer chromatography on a layer of silica gel G developed in chloroform/methanol/acetic acid/water (50:25:8:4, v/v). In all cases, recovered PAF included both cell-associated and that released in the medium. The PAF standard (1-O-hexadecyl-2-Oacetyl-sn-glycero-3-phosphocholine; C16-PAF; Biomol) was visualized with I 2 vapor. Radioactive PAF was detected by scanning the silica plate with a Bioscan system 200 (Canberra Packard), and the corresponding area was isolated and scraped directly into vials to detect radioactivity by liquid scintillation counting. The results were evaluated as cpm of radioactivity incorporated in the area comigrating with PAF standard. Inhibition of PAF synthesis was expressed as described for AA release.
To confirm that PAF measured by incorporation of [
H]-acetate was truly 1-alkyl-2-[
3 H]acetyl-glycero-3-phosphocholine, the samples were treated with lipase A 1 (from Rhizopus arrhizus, Sigma) as previously described [9] . Briefly, the lipid extract from A23187-stimulated HLM was suspended in 2 ml of diethyl ether and incubated (24 h, 30°C) with 1 ml of borate buffer (0.1 M, pH 6.5) containing 10 mM CaCl 2 and 1750 U of lipase A 1 . At the end of the incubation, the diethyl ether was dried under N 2 and lipids were extracted with the technique of Bligh and Dyer. The radioactivity in the organic and aqueous phases was determined by liquid scintillation counting.
β-glucuronidase assay
β-Glucuronidase activity in supernatants and cell pellets was measured by a colorimetric assay, as previously described [42] .
Statistical analysis
The data are expressed as the mean ± SE of the indicated number of experiments. p values were determined using Student's paired t-test.
Results
Characterization of endogenous PLA 2 s in human lung macrophages
Initial experiments were performed to examine the expression of cPLA 2 s and sPLA 2 s in human lung macrophages. To explore the presence of cPLA 2 -α (GIVA), cPLA 2 -ζ (GIVF) and iPLA 2 (GVIA) in these cells, we carried out quantitative PCR (qPCR) analysis. mRNAs for cPLA 2 -α and iPLA 2 were detected in all 5 preparations of macrophages from different donors ( Table 1) . Using either the primer set given in "Materials and methods" or those used previously [24] , no PCR signal for cPLA 2 -ζ was detected up to 40 cycles. When these primers were used to analyze, as controls, mRNA from the human colon cell line HT-29 or from a human colon cancer biopsy, the expected size band for cPLA 2 -ζ was seen after 25 and 24 cycles, respectively (data not shown).
Stimulation of macrophages with LPS for 24 h induced on average a 7-fold increase of cPLA 2 -α expression (ΔCt in unstimulated macrophages: 8.42 ± 0.70, ΔCt in LPS-treated macrophages: 5.62 ± 0.38, p b 0.01). This time point was selected because preliminary experiments indicated that the effect of LPS on cPLA 2 -α expression was optimal at 24 h. An increased expression of cPLA 2 -α induced by LPS was detectable already after 8 h of incubation. However, at this time point the effect of LPS was not significant because of great sample variability (data not shown). LPS had no effect on iPLA 2 mRNA and did not induce expression of cPLA 2 -ζ (data not shown). Western blot analysis of cPLA 2 -α in human lung macrophages confirmed the presence of cPLA 2 -α protein by revealing a positive signal that comigrated with the recombinant cPLA 2 -α (Fig. 1 ). This analysis also showed a faster migrating band in macrophage lysates whose identity is not known (Fig. 1, lane 1) . It should be mentioned, however, that a portion of cPLA 2 -α into the cells is usually phosphorylated and appears as a band-shift. Thus, it is possible that the two bands represent unphosphorylated and phosphorylated forms of cPLA 2 -α. We next examined the expression and the release of several forms of sPLA 2 s in both resting and LPS-activated macrophages. To this aim, we carried out qPCR for sPLA 2 mRNAs and a highly sensitive timeresolved fluorescence immunoassay (TRFIA) for protein detection. In fact, western blot analysis of sPLA 2 s usually does not provide reliable results presumably because of the relatively low abundance of these proteins in mammalian cells. Cell lysates were analyzed for mRNA (Table 1 ) and protein ( Fig. 2) and culture medium was analyzed for protein. For human GIB (hGIB), a low level of mRNA was detected in 3 of 5 unstimulated samples. A very low level of hGIB protein was detected only in 1 of 5 unstimulated samples. Expression of this enzyme was not augmented in LPS-stimulated macrophages. A low level of human GIIA (hGIIA) mRNA was detected in all samples of unstimulated cells and it was not further increased by LPS stimulation. Interestingly, hGIIA protein was detected weakly in 2 of 5 unstimulated cells, but it was significantly induced in all samples of LPSstimulated macrophages (Fig. 2) . No release of hGIIA was detected in either unstimulated and LPS-stimulated cells. Human GIID (hGIID) was consistently detected at the mRNA level and hGIID protein was contained in 2 of 5 samples. No differences were observed between unstimulated and LPS-stimulated cells. No mRNA for human GIIE (hGIIE) and human GIIF (hGIIF) was detected in macrophages (Ct values N 40 cycles). However, the relative proteins were detected in, but not consistently released by, about 50% of samples. LPS had no effect on these sPLA 2 s. All samples examined were negative for human GIII (hGIII) mRNA and protein. Interestingly, mRNA for human GV (hGV) was not detected in any samples, whereas relatively high levels of hGV protein (300-2000 ng per 3 × 10 6 cells) were consistently detected in the cell lysates. Three of 5 culture medium samples also contained this enzyme (100-1200 ng per 3 × 10 6 cells). Expression and release of this sPLA 2 were not influenced by LPS stimulation. Messenger RNA for human GX (hGX) was detected at low level in most samples. Two of the 5 samples contain the protein both in the cell lysates and in the culture medium. LPS had no effect on hGX mRNA expression and protein content. Finally, macrophages showed clearly detectable levels of human GXIIA (hGXIIA) mRNA and protein (500-1400 ng per 3 × 10 6 cells), but they did not release it. LPS had no effect on this sPLA 2 . hGXIIB mRNA was not detected and the protein was not analyzed by TRFIA.
Together these results indicate that macrophages contain the following sPLA 2 s: hGXIIA N hGV N hGIID N hGIIE N hGIIF N hGX NhGIIA. These cells contain little, if any, hGIB and no hGIII. Only hGV and hGX appear to be released to a limited extent. It is interesting to note that hGIIE, hGIIF and hGV are present at the protein level, but no mRNA is detectable. LPS upregulates only the protein content of hGIIA and does not induce or enhance the release of any sPLA 2 s. 2 and sPLA 2 inhibitors on AA release induced by non receptor-mediated agonists PMA and Ca
Effect of cPLA
2+ -ionophore
To evaluate the role of cPLA 2 -α in catalyzing AA release from primary human lung macrophages, we studied AA release in the presence and absence of two highly-potent, cell permeable, and structurally-divergent inhibitors of cPLA 2 -α (Pyrrolidine-1 and AZ-1). The indole analog Me-Indoxam was used to study the role of extracellular sPLA 2 s in macrophage AA release. The structures of these inhibitors are shown in Fig. 3 . Me-Indoxam is a very potent inhibitor (IC 50 in in vitro assays b 100 nM) of hGIIA, hGIIE and hGV [40] . Me-Indoxam is modestly potent (IC 50 ∼ 200 nM) on hGX and poorly ⁎p b 0.05 vs. respective unstimulated. Fig. 3 . Structures of the cPLA 2 -α and sPLA 2 inhibitors used in this study.
inhibits (IC 50 N 2000 nM) hGIID, hGIIF, hGIII and hGXIIA [40] . Human GIB, GIIA, GIIF, GIII, GV and GX display relatively high specific activity for the hydrolysis of phospholipid vesicles, and thus, one or more of these enzymes may be involved in liberating AA from membrane phospholipids for the biosynthesis of the eicosanoids. On the other hand, hGIID, hGIIE and hGXIIA have orders of magnitude lower specific activity on phospholipid vesicles [40] , suggesting that they may not be involved in lipid mediator biosynthesis; their function may be more as ligands for sPLA 2 receptors rather than as lipolytic enzymes [32] . The second point about Me-Indoxam is that, unlike the cPLA 2 -α inhibitors, it cannot cross the plasma membrane of cells and thus, it is able to inhibit the action of the sPLA 2 only if the protein is present in the extracellular environment prior to phospholipid hydrolysis [29, 30] .
In the first group of experiments, [ 3 H]AA-labeled human lung macrophages were preincubated with increasing (0.01 μM to 10 μM) concentrations of AZ-1, pyrrolidine-1 or Me-Indoxam and then stimulated (30 min, 37°C) with PMA (1 μM) or A23187 (1 μM). These two stimuli mobilize AA through distinct mechanisms [45] . Under these conditions, the release of AA induced by PMA and A23187 in four experiments was 10.5 ± 1.1% and 12.6 ± 1.1% of total cellular AA, respectively. Fig. 4 shows that preincubation with AZ-1 or pyrrolidine-1 dose-dependently inhibited the release of AA from both PMA-and A23187-stimulated human lung macrophages. In contrast, preincubation of macrophages with Me-Indoxam had little, if any effect on AA release, with less than 20% inhibition at the highest dose tested of 10 μM (Fig. 4) . None of the inhibitors influenced the spontaneous release of AA from macrophages when tested up to 10 μM (unstimulated: 3.2 ± 0.5 of total cellular AA; AZ-1: 3.4 ± 0.5; pyrrolidine-1: 3.1 ± 0.4; Me-Indoxam: 3.2 ± 0.6). The inhibitory effect of AZ-1 and pyrrolidine-1 became significant at 0.1 μM and led to an almost complete suppression of AA release at 10 μM. In these experimental conditions, AZ-1 appeared to be more potent than pyrrolidine-1 since: 1) at the maximum concentration (10 μM) AZ-1 caused a more profound inhibition of PMA-and A23187-induced AA release (93.7 ± 0.6% and 94.8 ± 0.7%, respectively) than pyrrolidine-1 (86.3 ± 1.5% and 87.4 ± 1.0%, respectively); and 2) the IC 50 values of AZ-1 (330 ± 90 nM and 310 ± 70 nM, on PMA-and A23187-induced release, respectively) were about two-fold lower than those of pyrrolidine-1 (690 ± 210 nM and 510 ± 160 nM, respectively). PMA and A23187 have been shown to have a synergistic effect on AA mobilization [46, 47] . We therefore determined whether AZ-1 or pyrrolidine-1 were also effective inhibitors of AA release induced by a combination of the two stimuli. As expected, simultaneous stimulation of macrophages with PMA and A23187 generated a release of AA (19.5 ± 1.8% of total cellular AA) that was almost two-fold higher than that induced by the two stimuli alone. Fig. 5 shows that both AZ-1 and pyrrolidine-1 effectively inhibited AA release induced by the combination of PMA and A23187. The IC 50 values (280 ± 110 nM and 800 ± 230 nM for AZ-1 and pyrrolidine-1, respectively) were comparable to those obtained in the previous set of experiments when macrophages were stimulated with PMA or A23187 alone, and the results confirmed that AZ-1 was more potent than pyrrolidine-1. Me-Indoxam had no significant effect on AA release induced by PMA and A23187 in combination (Fig. 5) . These results indicate that cPLA 2 -α is largely responsible for AA release induced by PMA and A23187 from human lung macrophages.
3.3. Effect of cPLA 2 -α and sPLA 2 inhibitors on AA release induced by receptor-mediated agonists PPD and LPS
We next studied the effect of cPLA 2 -α and sPLA 2 inhibitors on AA release induced by two physiological agonists of lung macrophages, PPD and LPS. PPD is the main extracellular protein product of M. tuberculosis and it is the major antigenic component eliciting the immune response against this microorganism [48] . PPD is a complex mixture of proteins, polysaccharides, peptidoglycan and lipoarabinomannan that activates cytokine production in human monocytes presumably by interacting with Toll-like receptor-2 (TLR2) [49, 50] .
The ability of PPD to induce AA mobilization in human macrophages has not been previously studied. Therefore, we initially examined whether incubation of human lung macrophages with PPD resulted in AA release. Fig. 6 shows that PPD (0.3-50 μg/ml) induced a concentration-dependent release of AA from macrophages, an effect that became significant at 3 μg/ml and was maximal at 30 μg/ ml (8.1 ± 1.0% of total cellular AA). In addition, since a recent report indicated that peptidoglycan or mannose-based pathogen-associated molecular patterns (PAMPs) induced AA release from human neutrophils [51] , we evaluated whether the effect of PPD was due to the presence of peptidoglycan or mannose-based PAMPs. To this purpose, HLM were incubated with increasing concentrations (0.3-50 μg/ml) of PGN from S. aureus (PGN-SA) or LAM from M. tuberculosis. PGN-SA was used because PGN from M. tuberculosis was not available. PGN-SA induced a concentration-dependent release of AA that was comparable to that induced by PPD (Fig. 6) . By contrast, LAM did not modify the spontaneous release of AA at all the concentrations examined (Fig. 6) . These results indicate that PPD-induced AA release is probably due to peptidoglycan component rather than to mannosebased PAMPs.
We next evaluated the effect of the PLA 2 inhibitors on the release of AA induced by PPD. Preincubation of macrophages with AZ-1 and pyrrolidine-1 inhibited in a dose-dependent manner the release of AA induced by an optimal concentration of PPD (30 μg/ml) (Fig. 7) . In contrast, Me-Indoxam had no effect on PPD-induced AA release (data not shown). Consistent with the results obtained with PMA and A23187, AZ-1 was more potent than pyrrolidine-1 to inhibit PPDinduced AA release (IC 50 values of 50 ± 20 nM and 120 ± 40 nM for AZ-1 and pyrrolidine-1, respectively). In these experiments, the highest concentration of AZ-1 used (10 μM) led to a small (≈13%) and non significant inhibition of spontaneous AA release. The highest concentration of pyrrolidine-1 and AZ-1 used, 10 μM, led to essentially complete inhibition of AA release (Fig. 7) .
To further explore the role of PLA 2 s in macrophages activated by physiological agonists, we evaluated the ability of PLA 2 inhibitors to block AA release induced by LPS, the main component of the Gramnegative bacterial cell wall. LPS is a well defined stimulus for macrophages, interacting with a receptor complex which includes TLR4 and CD14 [52] . Previous studies have shown that LPS is able to induce AA mobilization from murine and human macrophages [53, 54] . Fig. 8 shows that preincubation of macrophages with AZ-1 or pyrrolidine-1 dose-dependently inhibited AA release induced by LPS and completely suppressed it at 10 μM. The IC 50 of AZ-1 (90 ± 30 nM) and pyrrolidine-1 (140 ± 30 nM) were comparable to those obtained for inhibition of AA release induced by PPD. The sPLA 2 inhibitor Me-Indoxam had no effect on LPS-induced AA release (data not shown). Together these results indicate that the cPLA 2 -α is the main enzyme involved in AA mobilization induced by two independent, receptor-mediated stimuli in human macrophages.
Effect of cPLA 2 inhibitors on PAF synthesis from human lung macrophages
Different pathways can be involved in the synthesis of PAF in macrophages [10] . PAF production may occur through the deacylation-acetylation pathway, which is dependent on PLA 2 -mediated hydrolysis of 1-alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine, with formation of 1-alkyl-2-lyso-sn-glycero-3-phosphocholine (lyso-PAF), that is in turn acetylated to give PAF. Alternatively, lyso-PAF can be formed by PLA 2 -mediated hydrolysis of phosphatidylethanolamine (PE) followed by transacylation of lyso-PE by CoA-independent transacylase using 1-alkyl-2-acyl-sn-glycero-phosphocholine as the acyl donor to give lyso-PAF, which is in turn acetylated to give PAF. Finally, PAF can be synthesized by the de novo pathway that involves the transfer of phosphocholine from CDP-choline to 1-alkyl-2-acetylglycerol. The first two pathways, but not the third, are dependent on PLA 2 activity. The above mentioned experimental results show that two, structurally-distinct inhibitors of cPLA 2 -α blocked essentially all of the AA release in macrophages induced by multiple agonists, and thus we used these inhibitors to study the role of this enzyme in PAF production. We preincubated (30 (1 μM) were hydrolyzed by lipase A 1 , which cleaves 1-acyl, but not 1-alkyl linkage at the sn-1 position. Radioactivity remaining as phospholipid after lipase A 1 hydrolysis was 84 ± 16%, indicating that the majority of PAF produced by A23187-stimulated HLM was 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine. Both AZ-1 and pyrrolidine-1 inhibited in a dose-dependent manner PAF generation in human macrophages (Fig. 9 ). The sPLA 2 inhibitor Me-Indoxam had no effect on A23187-induced PAF production (data not shown). It should be noted that inhibition of PAF synthesis by AZ-1 and pyrrolidine-1 was not complete and reached a maximum of approximately 70% at a concentration of inhibitors of 10 μM. There was no difference in the inhibitory effect of AZ-1 and pyrrolidine-1 on PAF synthesis (Fig. 9) . The concentrations required to reach halfmaximal PAF inhibition were 275 ± 92 and 290 ± 104 nM for AZ-1 and pyrrolidine-1, respectively. These results indicate that cPLA 2 -α activity is required for the majority of the PAF produced in response to this agonist, but suggest that about 30% of the PAF in A23187-stimulated macrophages is made by a cPLA 2 -α-independent process. However, we cannot rule out the possibility that cPLA 2 -α is required for 100% of the PAF synthesis, but that the cPLA 2 -α substrates that give rise to lyso-PAF have interfacial K M values for the interaction with cPLA 2 -α that are lower than the substrates primarily utilized for AA liberation thus leading to a higher concentration of cPLA 2 -α inhibitor required for complete inhibition. We refrained from using cPLA 2 -α inhibitor at concentrations N10 μM because of concern about non-specific effects.
3.5. Effect of cPLA 2 -α and sPLA 2 inhibitors on exocytosis in human lung macrophages Activation of endogenous PLA 2 and AA mobilization have been suggested to be required for exocytosis in human neutrophils and eosinophils [55, 56] . We therefore tested the PLA 2 inhibitors for their effect on the release of β-glucuronidase, a lysosomal enzyme used as a marker of exocytosis, from human lung macrophages. In these experiments, macrophages were preincubated with AZ-1, pyrrolidine-1 or Me-Indoxam before the addition of Ca 2+ ionophore A23187. Fig. 10 shows that none of the inhibitors, at concentrations up to 10 μM, were able to significantly influence the release of β-glucuronidase either spontaneous or induced by A23187.
Discussion
In this study we characterized the main isoforms of PLA 2 s expressed in primary human macrophages. These cells contain cPLA 2 -α and iPLA 2 , but not cPLA 2 -ζ. In addition, macrophages express mRNA and/or contain the protein of several sPLA 2 s. We also provide strong evidence that cPLA 2 -α is a critical enzyme for the release of AA which is then available for conversion to eicosanoids. This evidence is based on the use of two structurally-divergent cPLA 2 -α inhibitors, pyrrolidine-1 and AZ-1, that cause almost complete suppression of AA release induced by various stimuli. Furthermore, both cPLA 2 -α inhibitors reduce by 70% the generation of PAF from macrophages. In contrast, a cell-impermeable sPLA 2 inhibitor, Me-Indoxam, has no effect on AA release and PAF synthesis.
A number of novel observations emerged from this study. First, human macrophages contain a wide profile of sPLA 2 s which include GIIA, GIID, GIIE, GIIF, GV, GX and GXIIA. Among these sPLA 2 s, only GIIA is upregulated by LPS, a classical stimulus to induce gene transcription in macrophages. LPS neither enhanced the other sPLA 2 s constitutively expressed by macrophages (GIID, GIIE, GIIF, GV, GX and GXIIA) nor induced the expression of GIB and GIII, which are undetectable in resting cells. However, LPS significantly upregulated the expression of cPLA 2 -α. These results are in line with previous observation in rat liver macrophages [57] and in U937 cell line [58] .
An intriguing observation of this study was that some sPLA 2 s were detected at the protein level without measuring any mRNA signal. We previously showed by a novel mass spectrometry method that human lung macrophages contain hGV [59] . This method is unambiguous since it is based on the firm detection of a hGV-derived peptide. It is not clear why mRNA for hGV and other sPLA 2 s was not detected. Perhaps, the mRNA is rapidly degraded while the protein accumulates in storage granules in macrophages. Another possibility is that some species of sPLA 2 s, released by other cells in the lung in vivo, can be taken up by macrophages via pino/endocytosis, which is a well known phenomenon occurring in these cells [60] . Indeed, lung surfactant and alveolar fluid contain relatively large quantities of sPLA 2 s [61, 62] . Thus, it is conceivable that macrophages can internalize these enzymes into phagolysosomes or other intracellular compartments while they are in the lung tissue.
In spite of the large number of sPLA 2 s expressed in macrophages, these enzymes are poorly released from macrophages. Only GV and GX were detected in the supernatants and the rate of release was not influenced by LPS. This raises the question of the role of these enzymes as intracellular mediators. In this regard, our results, showing a clear role of cPLA 2 -α in AA release and PAF production, do not rule out a role for one or more sPLA 2 s in these processes. As noted above, Me-Indoxam is not cell permeable, and thus it is possible that an intracellular action of sPLA 2 s could be involved in AA release and PAF production. The fact that the cPLA 2 -α inhibitors block all of the AA release argues that if an intracellularly active sPLA 2 is involved, it should act by augmenting the action of cPLA 2 -α, as shown in other cell systems [25, [28] [29] [30] [31] . For example, Satake et al. demonstrated that mouse peritoneal macrophages from GV-deficient mice release 50% less AA in response to opsonized zymosan as compared to cells from wild type mice [25] . In these cells, MeIndoxam has no effect on AA release (Gelb, M.H. unpublished data). Furthermore, TLR2-dependent activation of cPLA 2 -α and eicosanoid generation in mast cells from GV-deficient mice were markedly reduced [31] . Indeed, we have shown that the rat gastric mucosal cell line RGM1 uses both cPLA 2 -α and GIIA in a coordinate way to release AA leading to prostaglandin E 2 formation [30] . Similar data were obtained with hGIIA transfected HEK293 cells [29] . In both these cells, GIIA acts prior to secretion into the culture medium and the failure of Me-Indoxam to block the action of this enzyme is due to the inability of the compound to cross cell membranes to come in contact with the sPLA 2 in the secretory compartment [29, 30] . We are not aware of any potent sPLA 2 inhibitor that is cell permeable, and efforts are underway in the author's laboratory to remedy this problem. Until such compounds become available, we cannot reliably probe for the involvement of one or more sPLA 2 in AA release from human macrophages. Attempts to knockdown GV in human lung macrophages by RNA interference were not performed since no mRNA for this enzyme could be detected by qPCR (Table 1 ). The present data showing no effect of Me-Indoxam on AA release and PAF production from human lung macrophages suggests that an sPLA 2 in the culture medium is probably not involved.
Another novel observation in this study is the ability of PPD to induce AA release from human macrophages. This protein derivative of M. tuberculosis has been previously shown to induce cytokine synthesis in human monocytes, the precursors of tissue macrophages [49] . Our data demonstrate that PPD also initiates the AA metabolic cascade in human macrophages and that this effect is mimicked by similar concentrations of PGN from S. aureus, but not of LAM from M. tuberculosis. These observations are in agreement with a recent study showing that PGN from different bacteria induces AA release from human neutrophils at concentrations of 1-30 μg/ml whereas mannose-based PAMP induced a significant release of AA at concentrations higher than 5 mg/ml [51] . Since PPD and PGN have been shown to interact with TLR2 [50, 63] , it is likely that activation of cPLA 2 -α in macrophages occurs through the engagement of this receptor even though a role for other pattern recognition receptors cannot be ruled out. Previous data have shown that binding of LPS to TLR4 promotes AA release in murine macrophages [54] . Our data, showing that both PPD and LPS induce AA mobilization in human macrophages, indicate that cPLA 2 -α can be activated by engagement of different TLRs.
Interestingly, neither AZ-1 nor pyrrolidine-1 influenced basal AA release in resting macrophages, suggesting that cPLA 2 -α is exclusively required for agonist-induced AA release. It is possible that other PLA 2 s, such as the Ca 2+ -independent PLA 2 (GVI), are primarily involved in the basal turnover of AA in quiescent macrophages [64] . The recent availability of mice deficient in this enzyme may help to resolve this issue [65] , at least for murine macrophages.
Activation of cPLA 2 -α does not seem to be required for exocytosis in human macrophages. Studies with human neutrophils and eosinophils suggest the involvement of one or more PLA 2 s in degranulation [55, 56] , but these studies were carried out with nonspecific inhibitors of PLA 2 including the highly reactive p-bromophenacylbromide. Studies in neutrophils with highly potent and specific PLA 2 inhibitors are warranted.
The present study is the first extensive evaluation of PLA 2 enzymes in human macrophages purified ex vivo. Our data, showing that the generation of AA can be efficiently suppressed by cPLA 2 -α inhibitors have important pharmacological implications. First, these compounds are highly effective on primary macrophages which are one of the major cellular source of lipid mediators in the lung. Second, the capacity of the cPLA 2 -α inhibitors to block or reduce simultaneously the production of the two major classes of lipid mediators, eicosanoids and PAF, potentially endows these molecules with a very potent antiinflammatory activity. Finally, the observation that AZ-1 and pyrrolidine-1 are effective at submicromolar concentrations when macrophages are stimulated by physiological agonists (PPD and LPS) provides a rationale for the use of these inhibitors in the treatment of inflammatory lung diseases. It should be noted that some eicosanoids derived from cPLA 2 -α activity, such as PGE 2 , may exert antinflammatory activities and, therefore, their suppression may results in the exacerbation of lung inflammation. Thus, further studies are necessary to fully evaluate the in vivo effects of cPLA 2 -α inhibitors such as AZ-1 and pyrrolidine-1.
